Since the first report of the use of intravesical BCG for the treatment of recurrent superficial bladder tumours (Morales et al., 1976) , clinical trials have confirmed that BCG is an effective immunomodulator which provides superior results to those from chemotherapy (Lamm, 1992) . However, the mechanism of action of BCG remains unclear and therapy may cause significant side-effects (Lamm et al., 1992) .
Interferons have immunomodulatory and antiproliferative effects and may stimulate phagocytosis by polymorphonuclear leucocytes and increase macrophage and natural killer (NK) cell activity (Torti and Lum, 1987) . IFN-a has been used successfully clinically for the treatment of superficial bladder cancer, and patient responses are achieved with minimal local and systemic toxicity (Torti et al., 1988) . IFN-y (Prescott et al., 1990) and IL-2 (De Jong et al., 1990) are detected in the urine as part of the local immune response to BCG therapy.
In normal human urothelium T lymphocytes are present within the mucosal lining of the ureter and urinary bladder (El-Demiry et al., 1986) . Most of these CD3+ T lymphocytes are CD8+ (suppressor/cytotoxic), although CD4+ (helper/ inducer) cells are present. Monocytes/macrophages are found less frequently.
After repeated BCG instillations for superficial bladder cancer, mononuclear infiltrates are induced in the bladder wall of the patient. Infiltrating cells include T lymphocytes and smaller numbers of macrophages and B lymphocytes (De Boer et al., 1991a) . Analysis of mucosal bladder leucocyte subpopulations shows that most cells are lymphocytes which are associated with macrophages and eosinophils (Peuchmaur et al., 1991) . The major leucocyte subpopulation is the CD4+ T lymphocyte, while NK cells are uncommon and do not appear to make a major contribution to the anti-tumour activity of BCG (Ratliff et al., 1986) .
Clinical studies showed a marked increase in the number of leucocytes, mostly granulocytes, in the urine 24 h after repeated BCG instillations (De Boer et al., 1991b) . Monocytes/macrophages and lymphocytes, mostly CD4+ T cells, were also present. After treatment, the absolute numbers of anl subpopulations increased, but the increase in monocytes/macrophages was most marked.
As monocytes/macrophages and lymphocytes appeared to be the major leucocyte subpopulations involved in the immune response to BCG, we developed a cytotoxicity assay in which monocytes and lymphocytes were pretreated with BCG and cytokines and then co-incubated with bladder tumour cells to determine the anti-tumour activity of immune cells.
Materials and methods

Target cells
The UCRU-BL-17 cell line was derived from a transitional cell carcinoma (Russell et al., 1988) (De Weger et al., 1986 (Figure 1 ) (r2 = 0.82, P= 0.0343, for UCRU-BL-17; r2 = 0.218, P= 0.5332, for 5637). Decreasing significant P-values with increasing BCG were seen for the T24 cells (5-50 ggml-', P=0.1747; 5-250 jg ml-', P = 0.0268; and 5-500 gg ml-', P = 0.0062).
To confirm that the release of [3H]thymidine represented a cytotoxic effect, we selected two cell lines UCRU-BL-17, which was sensitive to effector-mediated killing, and J82, which showed a dose-dependent direct response to BCG, and exposed them to BCG for 72 h to compare the cytotoxicity assay method with cell counts (Figure 2 (Figure 3) . Unstimulated lymphocytes had a significantly higher cytotoxic activity (19.6% ± 4.6%) than unstimulated monocytes/ macrophages (6.8%-1.6%) (P = 0.0041) against the cell line UCRU-BL-17, and both were significantly higher than the spontaneous release by target cells alone (monocytes vs control P = 0.00 13; lymphocytes vs control P = 0.0001) ( Figure  4 ). This trend was observed for the 5637 and J82 cell lines but was not statistically significant (data not shown). As the UCRU-BL-17 cell line appeared to be more sensitive to effector-mediated killing, it was selected to test BCG-and cytokine-enhanced effector cytotoxicity. The cytotoxic activity of both monocytes/macrophages and lymphocytes against UCRU-BL-17 target cells was increased by pre- (Figure 6 ). Similar significant differences were seen when using the J82 target line (data not shown).
To determine whether BCG pretreatment made target cells more susceptible to effector-mediated cytolysis, UCRU-BL-17 cells were pretreated for 48 h with BCG. Treated targets were no more susceptible than untreated targets to lysis by BCG-or cytokine-stimulated monocytes/macrophages or lymphocytes (data not shown).
Monocytes and lymphocytes were isolated from the peripheral blood of two pretherapy bladder cancer patients. The patients were male, 61 (patient 1) and 74 (patient 2) years old, and information on previous exposure to BCG was not available from their medical records. BCG-stimulated effector cells isolated from patient 2 but not from patient 1 (monocytes, P = 0.009; lymphocytes, P = 0.0947) (Figure 7 ). effects of specific cytokines on effector-mediated cytotoxicity. The cytokines IFN-a2b, IFN-y and IL-2 at concentrations of 10, 100 or 1000 U ml-I were added to the tumour target cells alone (control) or with effectors. IFN-a2b and IL-2 caused an increase in percentage specific release by UCRU-BL-17 cells (for IFN-o2b: for an increase of 10 to 100 U ml-', P=0.5715, 10 to 1000Uml-', P=0.5119, r2=0.675, P=0.1783; for IFN-7y: 10 to l00UmlP', P=1, 10 to 1000 U ml-', P = 0.8046, r2= 0.068, P = 0.7391; for IL-2: 10 to 100Uml'l, P=0.8977, r2=919, P=0.1836), but this was not statistically significant (Table I ). There was no observed increase for the other three cell lines (data not shown). IFN-a2b, IFN-y and IL-2 did not significantly enhance monocyte/macrophage or lymphocyte killing of any of our cell lines at the doses tested (data not shown).
Combinations of BCG and cytokines
The effects of BCG combined with IFN-m2b, IFN-'y or IL-2 at the concentrations stated above were investigated using the four cell lines. In case the effects were due to timing, BCG and IFN-a2b were added together or sequentially, one 6 h after the other, in either order. We found neither evidence of supra-additivity nor any advantage in adding the biological response modifiers together as compared with separately in either order (data not shown).
T-cell/natural killer (NK) cell cytotoxicity T cells and NK cells were compared with peripheral blood mononuclear cells (PBMCs) and lymphocytes in the above assay at 72 h and 144 h (Figure 8 ). The percentage specific release for all populations increased with time and BCG concentration. Addition of 250 pg ml-' BCG to effectors increased their 72 h percentage specific release as follows: control, 0% to 7.2%; PBMCs, 16.1% to 30.6%; lymphocytes, 11.7% to 25.4%; T cells, 4.4% to 6.3%; and T cells + 20% NK cells, 5.7% to 7.2%. These increases were not statistically significant (P = 0.1732). At 144 h the percentage specific release in all effector populations strongly correlated with BCG concentration (control, r2 = 0.727, P = 0.3499; PBMCs, r2 = 1, P =0.0066; lymphocytes, r2 = 0.996, P = 0.0421; T cells, r2=0.941, P=0.1557; and T cells+20% NK cells, r2 = 0.998, P = 0.0275).
Discussion
BCG enhanced cytotoxic activity of monocytes and lymphocytes against bladder cancer cell lines in vitro and also had a small direct effect on these target cells. In four bladder tumour target lines, BCG mediated an increase in percentage BCG enhances bladder tumour cell killing K Pryor et al W 805 specific release, accompanied by a decrease in cell numbers but not cell viability, suggesting an antiproliferative rather than a cytotoxic effect. BCG can bind in a dose-dependent manner to T24 cells (Mitzutani et al., 1991) and is internalised by both mouse and human bladder tumour cells (Becich et al., 1991) . Although direct cytotoxicity of BCG or cytokines alone was not demonstrable against bladder cancer cell lines , it could result from release of bacterial components during BCG degradation or from proliferation of intracellular bacteria.
Previous exposure of a donor to BCG failed to enhance in vitro BCG-mediated effector cytotoxicity, but effectors from two pretherapy bladder cancer patients showed different responses. An understanding of the basis of patient response variation may help to predict who would benefit from BCG immunotherapy.
Monocytes and lymphocytes have been identified in immune infiltrates in the bladder following BCG administration (De Boer et al., 1991a; Peuchmaur et al., 1991) and an intact thymus-dependent immune response is required for the anti-tumour activity of BCG (Ratliff et al., 1987; Ratliff, 1992) . Flow cytometric analysis indicated that lymphocyte fractions used in our study contained T, B and NK cells and some polymorphonuclear (PMN) cells, while the monocyte population was more homogeneous (78% CD14+). PBMCs and unsorted lymphocytes were more cytotoxic than sorted T cells or T cells+ 20% NK cells, which showed a slower response, requiring over 144 h. Each effector group was more cytotoxic at 144 h than at 72 h. Others have shown that PBMCs incubated with BCG increase cytotoxicity to a maximum at 7 days but are unable to demonstrate NK-mediated killing of bladder cancer cell lines.
The greater cytotoxic activity of unstimulated lymphocytes compared with unstimulated monocytes/macrophages may be due to cytokine release by effectors in the lymphocyte frac- tion. We found that SNs from BCG-activated monocytes/ macrophages and lymphocytes increased target cell lysis, indicating that BCG cytotoxicity is largely cytokine mediated. Possible candidate cytokines include tumour necrosis factor alpha (TNF-a), IFN-7, IL-1p and IL-6 (Kurisu et al., 1995) . This is supported by clinical studies which show that BCG therapy induces the presence of IL-1, IL-2, IL-6, TNF-a (De Boer et al., 1992) and IFN-y (Prescott et al., 1990) in urine, probably derived from activated lymphocytes and, similarly, IFN-y, IL-2, TNF-o and TNF-P are found in SNs of BCG-activated PBMCs in vitro . In other studies, CD8+/CD56+ lymphocytes, but not CD4+ cells or macrophages, have been found to be responsible for BCG-induced cytolysis .
Both IFN-a2b and IL-2, but not IFN-y, caused a small increase in the percentage specific release by UCRU-BL-17 cells. The mechanism underlying these effects was not clear, although IFN-a has proven effectiveness in vivo (Torti et al., 1988) . Others have shown that IL-2 at 10U ml' induces LAK activity against bladder cancer cell lines after 3 days, but that maximum activity requires 6 days with 1000 U ml1' (Jackson et al., 1992) . Tumour cells modified to express IL-2 and injected into tumour-bearing mice have been shown to give better anti-tumour effects than cisplatin or IFN-yproducing cells against MBT2 mouse tumours, but no memory was established in 'cured' mice (Connor et al., 1993) . IL-2 also contributes to the maturation of effector cells and stimulates IFN-y production, inducing activation of macrophages and cytotoxic T cells (Ikemoto et al., 1990) . The increase to maximum cytotoxicity by monocytes incubated with IL-2 occurs at 8-16 days (Higashi et al., 1992) . The assay time which we used may not be sufficient to demonstrate maximum IL-2-mediated increases in effector cytotoxicity.
In the assay used, BCG was more efficient than cytokines in stimulating effector cells alone. The response of macrophages has been shown to depend on the activating agent.
Thus, lymphokine-triggered cytotoxic activity in bone marrow-derived phagocytes declines after 24 h, but that elicited by bacteria persists (Keller et al., 1990) . Furthermore, the secretion of IL-6 and prostaglandin E2 (PGE2) is enhanced by bacteria but not by lymphokines. In our experiments, a combination of BCG and cytokines was not supra-additive at the concentrations tested and an isobolographic analysis was not therefore justified (Goldstein et al., 1989) .
The bladder cancer lines used in this study differed in susceptibility to cytotoxic effects of BCG. Preincubation with BCG induced a dose-dependent increase in cytotoxic activity towards UCRU-BL,4l7, but not towards 5637, T24 or J82 bladder cancer cells. Others have also found that effector cell killing is independent of the histological grade of the parent tumour and the donor of the effector cells (Jackson et al., 1992) . Possible explanations for differences in target cell susceptibility relate to expression of cytokine receptors or tumour-associated antigens. The UCRU-BL-17 line has been established much more recently than the other cell lines, which may have undergone changes in resistance over their long period of tissue culture.
The mechanisms of BCG action are unclear but involve both direct effects possibly mediated via internalised bacteria and indirect immune effects involving immune infiltrates found in the bladder wall and urine of patients treated with BCG instillations. In vitro, the cytotoxic effect of monocytes/ macrophages and lymphocytes is significantly enhanced by BCG, indicating that this could be an important indirect immune effect of BCG. Further work is needed to clarify the role of effector cells, using specific defined leucocyte subpopulations, and to understand the differential sensitivity of target cells to cytotoxic effects.
